New drug class for heart patients shows bleeding risk that demands caution

Factor XI inhibitors, a promising new class of cardiovascular drugs, carry a serious bleeding risk for high-risk patients that researchers say warrants careful clinical scrutiny. The finding matters to pharmaceutical companies developing these agents, hospital networks implementing new protocols, and policymakers determining coverage and approval pathways.

Originaltitel: Factor XI inhibitors in patients with cardiovascular disease and a high risk of bleeding: a cautionary tale